Francis Chou
Chou Associates Management
Francis Chou GlaxoSmithKline PLC ADR stake
total: 81
Chou Associates Management GSK trades
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2013 Q4
- Held for:
- 13 quarters
- Latest activity:
- 2017 Q1
According to 2026 Q2 report, Francis Chou doesn't hold any GlaxoSmithKline PLC ADR (GSK) shares. To date, the estimated cost basis is nearly $33.19 for "buy" trades and estimated average "sell" price is $24.1. Chou Associates Management first purchased GSK in 2013 Q4, initially acquiring 14,400 shares. Since the initial investment in GlaxoSmithKline PLC ADR (GSK), Chou Associates Management has made 1 more transaction.
When did Francis Chou sell GlaxoSmithKline PLC ADR (GSK)?
Francis Chou sold off the entire GlaxoSmithKline PLC ADR (GSK) position in 2017 Q1.
When did Francis Chou buy GlaxoSmithKline PLC ADR (GSK)?
Francis Chou first invested in GlaxoSmithKline PLC ADR (GSK) in 2013 Q4 at the reported quarter-end price of $33.19 per share.
What's the cost basis of Chou Associates Management's GSK stake?
The estimated cost basis for GlaxoSmithKline PLC ADR (GSK) stake is around $33.19 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $33.19
- Weighted AVG sell price:
- $24.10
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.